Market Overview

ACADIA Pharma Shares Move Higher as JMP Boosted Price Target from $16 to $27

Related ACAD
These were The Top 10 Trending Stocks This Week
Biotechs Are Ripping Following IPAB Ruling
The Vetr community has downgraded $ACAD to 4-Stars (Vetr)

JMP Securities maintains ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) with a Market Outperform and raises the price target from $16.00 to $27.00.

The stock has opened up more than 4 percent higher. With the stock last trading at $19.45, the firm's new price target implies potential upside of about 39 percent.

Latest Ratings for ACAD

Jun 2016Bank of AmericaDowngradesBuyNeutral
May 2016Leerink SwannDowngradesOutperformMarket Perform
Feb 2016JP MorganMaintainsNeutral

View More Analyst Ratings for ACAD
View the Latest Analyst Ratings

Posted-In: News Price Target Analyst Ratings


Related Articles (ACAD)

View Comments and Join the Discussion!